TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

Antimicrobial Agents and Chemotherapy
Hilde AzijnLaurence T Rimsky

Abstract

Nonnucleoside reverse transcriptase inhibitors (NNRTIs) have proven efficacy against human immunodeficiency virus type 1 (HIV-1). However, in the setting of incomplete viral suppression, efavirenz and nevirapine select for resistant viruses. The diarylpyrimidine etravirine has demonstrated durable efficacy for patients infected with NNRTI-resistant HIV-1. A screening strategy used to test NNRTI candidates from the same series as etravirine identified TMC278 (rilpivirine). TMC278 is an NNRTI showing subnanomolar 50% effective concentrations (EC50 values) against wild-type HIV-1 group M isolates (0.07 to 1.01 nM) and nanomolar EC50 values against group O isolates (2.88 to 8.45 nM). Sensitivity to TMC278 was not affected by the presence of most single NNRTI resistance-associated mutations (RAMs), including those at positions 100, 103, 106, 138, 179, 188, 190, 221, 230, and 236. The HIV-1 site-directed mutant with Y181C was sensitive to TMC278, whereas that with K101P or Y181I/V was resistant. In vitro, considerable cross-resistance between TMC278 and etravirine was observed. Sensitivity to TMC278 was observed for 62% of efavirenz- and/or nevirapine-resistant HIV-1 recombinant clinical isolates. TMC278 inhibited viral replication a...Continue Reading

References

Oct 1, 1990·Antiviral Research·M N Prichard, C Shipman
Aug 1, 1988·Journal of Virological Methods·R PauwelsE De Clercq
Aug 1, 1984·The Journal of Infectious Diseases·M C Berenbaum
Mar 25, 1981·Journal of Molecular Biology·T F Smith, M S Waterman
May 1, 1993·Journal of Acquired Immune Deficiency Syndromes : JAIDS·S OieD I Abrams
Jan 1, 1994·Advances in Protein Chemistry·D C Carter, J X Ho
Aug 21, 2001·Journal of Acquired Immune Deficiency Syndromes : JAIDS·C BalottaUNKNOWN ICONA Study Group
Dec 31, 2002·The Lancet Infectious Diseases·Luc PerrinSabine Yerly
Aug 22, 2003·Proceedings of the National Academy of Sciences of the United States of America·Pin-Fang LinRichard Colonno
Aug 1, 1958·Experimental Cell Research·J P KALTENBACHW B LYONS
Oct 31, 2003·The Journal of Biological Chemistry·Mette M RosenkildeThue W Schwartz
Jul 23, 2004·Antiviral Chemistry & Chemotherapy·Zhijun ZhangZhi Hong
Nov 16, 2006·HIV Medicine·B GazzardUNKNOWN Writing Committee, British HIV Association
Jun 19, 2007·Journal of Virological Methods·H VermeirenUNKNOWN Virco Clinical Response Collaborative Team
Nov 28, 2007·Proceedings of the National Academy of Sciences of the United States of America·Chong FangRobin M Hochstrasser
Jan 31, 2008·Proceedings of the National Academy of Sciences of the United States of America·Kalyan DasEddy Arnold
May 16, 2008·The New England Journal of Medicine·Sharon A RiddlerUNKNOWN AIDS Clinical Trials Group Study A5142 Team

❮ Previous
Next ❯

Citations

Oct 9, 2002·Medicinal Research Reviews·Erik De Clercq
Nov 21, 2013·Enfermedades infecciosas y microbiología clínica·Piedad Arazo Garcés, Ignacio de los Santos Gil
Nov 21, 2013·Enfermedades infecciosas y microbiología clínica·Arkaitz ImazJosep M Llibre
Jun 26, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hiroyuki GatanagaShinichi Oka
May 14, 2010·The Journal of Antimicrobial Chemotherapy·Elizabeth C ReumanRobert W Shafer
Mar 22, 2013·The Journal of Antimicrobial Chemotherapy·Darren M MossAndrew Owen
May 1, 2013·The Journal of Antimicrobial Chemotherapy·Lourdes AntaUNKNOWN Drug Resistance Platform of the Spanish AIDS Research Network
Oct 4, 2012·Current Opinion in HIV and AIDS·Bisrat K Abraham, Roy Gulick
Apr 1, 1970·British Journal of Haematology·J H SteadmanE R Huehns
Jun 27, 2012·Antimicrobial Agents and Chemotherapy·Eugene L AsahchopCécile L Tremblay
Dec 30, 2010·Antimicrobial Agents and Chemotherapy·Nadine Cécile Luise ZembruskiJohanna Weiss
Nov 30, 2011·Antimicrobial Agents and Chemotherapy·Susan M SchaderMark A Wainberg
Dec 1, 2010·Retrovirology·Danielle Perez BercoffJean Ruelle
Apr 1, 2011·Future Microbiology·Shiro Ibe, Wataru Sugiura
Sep 7, 2013·Journal of the International AIDS Society·Iris UsachJosé-Esteban Peris
Apr 22, 2014·Journal of the International AIDS Society·Miłosz ParczewskiMagdalena Leszczyszyn-Pynka
Dec 19, 2013·Antiviral Research·Luis Menéndez-Arias, Mar Alvarez
Sep 3, 2010·Annual Review of Pharmacology and Toxicology·Erik De Clercq
Sep 5, 2013·Antimicrobial Agents and Chemotherapy·Darren M MossAndrew Owen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.